DK1480679T3 - Farmaceutisk formulering af iressa, der omfatter et vandoplöseligt cellulosederivat - Google Patents

Farmaceutisk formulering af iressa, der omfatter et vandoplöseligt cellulosederivat

Info

Publication number
DK1480679T3
DK1480679T3 DK03706732T DK03706732T DK1480679T3 DK 1480679 T3 DK1480679 T3 DK 1480679T3 DK 03706732 T DK03706732 T DK 03706732T DK 03706732 T DK03706732 T DK 03706732T DK 1480679 T3 DK1480679 T3 DK 1480679T3
Authority
DK
Denmark
Prior art keywords
iressa
water
pharmaceutical formulation
cellulose derivative
soluble cellulose
Prior art date
Application number
DK03706732T
Other languages
Danish (da)
English (en)
Inventor
Paul Richard Gellert
Michael Davis Parker
Matas Marcel De
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1480679(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0204392A external-priority patent/GB0204392D0/en
Priority claimed from GB0212462A external-priority patent/GB0212462D0/en
Priority claimed from GB0213267A external-priority patent/GB0213267D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1480679T3 publication Critical patent/DK1480679T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK03706732T 2002-02-26 2003-02-24 Farmaceutisk formulering af iressa, der omfatter et vandoplöseligt cellulosederivat DK1480679T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0204392A GB0204392D0 (en) 2002-02-26 2002-02-26 Pharmaceutical compound
GB0212462A GB0212462D0 (en) 2002-05-30 2002-05-30 Pharmaceutical compound
GB0213267A GB0213267D0 (en) 2002-06-11 2002-06-11 Pharmaceutical composition
PCT/GB2003/000803 WO2003072139A1 (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative

Publications (1)

Publication Number Publication Date
DK1480679T3 true DK1480679T3 (da) 2007-09-03

Family

ID=27767732

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03706732T DK1480679T3 (da) 2002-02-26 2003-02-24 Farmaceutisk formulering af iressa, der omfatter et vandoplöseligt cellulosederivat

Country Status (30)

Country Link
US (2) US20050163835A1 (pt)
EP (1) EP1480679B1 (pt)
JP (1) JP4544863B2 (pt)
KR (2) KR20100090726A (pt)
CN (1) CN1326569C (pt)
AR (1) AR038848A1 (pt)
AT (1) ATE362771T1 (pt)
AU (1) AU2003208444B2 (pt)
BR (1) BRPI0307786B8 (pt)
CA (1) CA2476587C (pt)
CO (1) CO5601038A2 (pt)
CY (1) CY1108026T1 (pt)
DE (1) DE60313956T2 (pt)
DK (1) DK1480679T3 (pt)
ES (1) ES2286406T3 (pt)
HK (1) HK1070585A1 (pt)
IL (2) IL163642A0 (pt)
IS (1) IS2462B (pt)
MX (1) MXPA04008307A (pt)
MY (1) MY135609A (pt)
NO (1) NO328658B1 (pt)
NZ (1) NZ534513A (pt)
PL (1) PL208114B1 (pt)
PT (1) PT1480679E (pt)
RU (1) RU2318518C2 (pt)
SA (1) SA03240043B1 (pt)
TW (1) TWI271193B (pt)
UA (1) UA76325C2 (pt)
UY (1) UY27682A1 (pt)
WO (1) WO2003072139A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL163689A0 (en) 2002-02-26 2005-12-18 Astrazeneca Ab Novel crystalline forms of the anti-cancer compound zd1839
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
GEP20084551B (en) 2004-05-06 2008-11-25 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
MY151003A (en) 2005-09-12 2014-03-31 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
EP3594248B1 (en) 2006-10-27 2021-08-04 Capsugel Belgium NV Hydroxypropyl methyl cellulose hard capsules and process of manufacture
CA2686964A1 (en) * 2007-06-06 2008-12-11 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI540132B (zh) * 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
CN102470109A (zh) * 2009-07-02 2012-05-23 惠氏有限责任公司 3-氰基喹啉片剂制剂及其应用
JP5779591B2 (ja) * 2009-12-22 2015-09-16 アッヴィ・インコーポレイテッド Ａｂｔ−２６３カプセル剤
JP4574742B1 (ja) * 2010-04-08 2010-11-04 有限会社ミールジャパン プロポリス組成物
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
EP2632436B1 (en) 2010-10-29 2018-08-29 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
WO2012071340A1 (en) 2010-11-23 2012-05-31 Metamagnetics Inc. Antenna module having reduced size, high gain, and increased power efficiency
US8722657B2 (en) 2010-11-23 2014-05-13 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
WO2012071374A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors
CN102631347B (zh) * 2012-05-03 2014-06-25 石药集团中奇制药技术（石家庄）有限公司 一种吉非替尼药物组合物及其制备方法
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR101332829B1 (ko) * 2013-05-31 2013-11-27 재단법인 통합의료진흥원 보중익기탕을 포함하는 폐암 치료용 조성물
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
KR101721831B1 (ko) * 2014-11-06 2017-03-31 주식회사 종근당 로베글리타존을 함유하는 경구 투여용 약제학적 조성물
WO2016096999A1 (en) 2014-12-19 2016-06-23 Synthon B.V. Pharmaceutical composition comprising gefifinib
DK3263110T3 (da) * 2015-02-26 2023-07-31 Takeda Pharmaceuticals Co Tablet, som omfatter et methoxyurinstofderivat og mannitolpartikler
KR101739731B1 (ko) * 2015-12-31 2017-05-25 환인제약 주식회사 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물
CN108096251B (zh) * 2016-11-24 2021-11-16 江苏恒瑞医药股份有限公司 一种吉非替尼药物组合物及其制备方法
CN107007562B (zh) * 2017-02-16 2020-10-27 南京优科制药有限公司 一种吉非替尼片剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608063A (en) * 1969-08-15 1971-09-21 Gilbert S Banker Molecular drug entrapment process and compositions
US4178376A (en) * 1977-01-21 1979-12-11 Interx Research Corporation Method for inducing rapid therapeutically effective antimalarial levels of certain selected conventional antimalarials
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9207988D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Topical composition
EP0716597A1 (en) * 1993-08-30 1996-06-19 Warner-Lambert Company Tablet coating based on a melt-spun mixture of a saccharide and apolymer
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB2306885B (en) * 1995-11-08 1999-07-14 Reckitt & Colmann Prod Ltd Supersaturated Pharmaceutical Compositions
CO4940469A1 (es) * 1997-03-05 2000-07-24 Sugen Inc Composicion oral de estabilidad mejorada que comprende un derivado de indolinona y una mezcla de gliceridos o esteres de polietilenglicol
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
IL163689A0 (en) * 2002-02-26 2005-12-18 Astrazeneca Ab Novel crystalline forms of the anti-cancer compound zd1839
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물

Also Published As

Publication number Publication date
CN1326569C (zh) 2007-07-18
NO20043866L (no) 2004-09-15
CN1638805A (zh) 2005-07-13
PL208114B1 (pl) 2011-03-31
BR0307786A (pt) 2004-12-07
JP2005523293A (ja) 2005-08-04
UY27682A1 (es) 2003-10-31
CA2476587A1 (en) 2003-09-04
TWI271193B (en) 2007-01-21
CY1108026T1 (el) 2013-09-04
ES2286406T3 (es) 2007-12-01
US20090186890A1 (en) 2009-07-23
DE60313956D1 (de) 2007-07-05
HK1070585A1 (en) 2005-06-24
IL163642A (en) 2007-07-24
TW200304379A (en) 2003-10-01
JP4544863B2 (ja) 2010-09-15
KR20100090726A (ko) 2010-08-16
BRPI0307786B1 (pt) 2018-03-13
RU2318518C2 (ru) 2008-03-10
PL372215A1 (en) 2005-07-11
KR20040088524A (ko) 2004-10-16
SA03240043B1 (ar) 2007-05-06
US20050163835A1 (en) 2005-07-28
IS7420A (is) 2004-08-24
CA2476587C (en) 2010-05-04
RU2004129280A (ru) 2005-06-10
IS2462B (is) 2008-11-15
BRPI0307786B8 (pt) 2021-05-25
ATE362771T1 (de) 2007-06-15
AU2003208444B2 (en) 2006-10-26
AU2003208444A1 (en) 2003-09-09
EP1480679B1 (en) 2007-05-23
MY135609A (en) 2008-05-30
NZ534513A (en) 2007-04-27
AR038848A1 (es) 2005-01-26
CO5601038A2 (es) 2006-01-31
EP1480679A1 (en) 2004-12-01
WO2003072139A1 (en) 2003-09-04
MXPA04008307A (es) 2004-11-26
PT1480679E (pt) 2007-07-18
UA76325C2 (uk) 2006-07-17
KR101002374B1 (ko) 2010-12-17
IL163642A0 (en) 2005-12-18
NO328658B1 (no) 2010-04-19
DE60313956T2 (de) 2008-05-15

Similar Documents

Publication Publication Date Title
DK1480679T3 (da) Farmaceutisk formulering af iressa, der omfatter et vandoplöseligt cellulosederivat
CY2017048I2 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
DK1615646T4 (da) Farmaceutiske formuleringer, der indeholder methylnaltrexon
DK1562946T5 (da) Nye xanthinderivater, deres fremstilling og deres anvendelse som lægemiddel
NO20054220D0 (no) Substituerte N-arylheterocykler, fremgangsmate for fremstilling derav og deres anvendelse som legemiddel
DK2298769T3 (da) Xanthinderivater, deres fremstilling og deres anvendelse som lægemiddel
NO20025879D0 (no) Acylfenylureaderivater, fremgangsmåte for fremstilling derav og deres anvendelse som et legemiddel
ATE380544T1 (de) Umhüllte feste darreichungsform
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
NO20053143D0 (no) Farmasoytiske sammensetninger omfattende en basisk, henholdsvis sur legemiddelforbindelse, en sufaktant og en fysiologisk akseptabel vannloselig syre henholdsvis base.
IS7667A (is) Nýjar bensimídazólafleiður
ATE336264T1 (de) Dispergierbare pharmazeutische zusammensetzungen
DE602004031776D1 (de) Piperidinamino-benzimidazol-derivate al respiratorisches syncytialvirus replikation inhibitoren
PT1501534E (pt) Formulacoes farmaceuticas
NO20054006D0 (no) Cykliske ureaderivater, fremstillingsfremgangsmate derav og farmasoytisk anvendelse av samme som kinaseinhibitorer
IS7298A (is) Platínuafleiða lyfjasamsetningar
NO20044322L (no) Benzoksanon-avledede forbindelser, deres fremstilling og anvendelse som medikament
DK1601363T3 (da) Anvendelse som lægemiddel af derivater af cholest-4-en-3-on, farmaceutiske sammensætninger indeholdende disse og nye derivater
DK1476196T3 (da) Oral formulering af fast oplösning for et aktive stof, der er tungtoplöseligt i vand
NO20054389D0 (no) Cyckloalkyl-substituerte alkansyrederivater, fremgangsmate for fremstilling og anvendelse derav som legemiddel
DK1663243T3 (da) Farmaceutisk formulering omfattende et pyrimidin-a-on-derivat coatet med en enterisk polymer
DK1750765T3 (da) Farmaceutisk antimykobakteriesammensætning omfattende et antituberkulöst lægemiddel
DE60221342D1 (de) Niedrig substituierte Hydroxypropylzellulose
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid